141 related articles for article (PubMed ID: 24407159)
1. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
Jung SH; Lee YK; Lee HJ; Choi NR; Vo MC; Hoang MD; Lim MS; Nguyen-Pham TN; Kim HJ; Lee JJ
Exp Hematol; 2014 Apr; 42(4):274-81. PubMed ID: 24407159
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Kim JE; Jin DH; Lee WJ; Hur D; Wu TC; Kim D
Pharmacol Res; 2013 May; 71():23-33. PubMed ID: 23428347
[TBL] [Abstract][Full Text] [Related]
4. Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Moeller I; Spagnoli GC; Finke J; Veelken H; Houet L
Cancer Immunol Immunother; 2012 Nov; 61(11):2079-90. PubMed ID: 22562379
[TBL] [Abstract][Full Text] [Related]
5. Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells.
Vo MC; Nguyen-Pham TN; Lee HJ; Jung SH; Choi NR; Hoang MD; Kim HJ; Lee JJ
Oncotarget; 2017 Jul; 8(28):46047-46056. PubMed ID: 28512265
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Spisek R; Charalambous A; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
Blood; 2007 Jun; 109(11):4839-45. PubMed ID: 17299090
[TBL] [Abstract][Full Text] [Related]
8. Immune mechanism of the antitumor effects generated by bortezomib.
Chang CL; Hsu YT; Wu CC; Yang YC; Wang C; Wu TC; Hung CF
J Immunol; 2012 Sep; 189(6):3209-20. PubMed ID: 22896634
[TBL] [Abstract][Full Text] [Related]
9. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.
Molavi O; Mahmud A; Hamdy S; Hung RW; Lai R; Samuel J; Lavasanifar A
Mol Pharm; 2010 Apr; 7(2):364-74. PubMed ID: 20030320
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
Straube C; Wehner R; Wendisch M; Bornhäuser M; Bachmann M; Rieber EP; Schmitz M
Leukemia; 2007 Jul; 21(7):1464-71. PubMed ID: 17495970
[TBL] [Abstract][Full Text] [Related]
12. Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
Lee JH; Kim C; Kim SH; Sethi G; Ahn KS
Cancer Lett; 2015 May; 360(2):280-93. PubMed ID: 25697480
[TBL] [Abstract][Full Text] [Related]
13. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib influences the expression of malignant plasma cells membrane antigens.
Tagoug I; Plesa A; Dumontet C
Eur J Pharmacol; 2013 Apr; 706(1-3):11-6. PubMed ID: 23458070
[TBL] [Abstract][Full Text] [Related]
15. Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.
Lee JC; Ahn KS; Jeong SJ; Jung JH; Kwon TR; Rhee YH; Kim SH; Kim SY; Yoon HJ; Zhu S; Chen CY; Kim SH
J Cell Biochem; 2011 Jun; 112(6):1552-62. PubMed ID: 21344490
[TBL] [Abstract][Full Text] [Related]
16. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
De Matteo M; Brunetti AE; Maiorano E; Cafforio P; Dammacco F; Silvestris F
Leuk Res; 2010 Feb; 34(2):243-9. PubMed ID: 19656567
[TBL] [Abstract][Full Text] [Related]
17. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
Terpos E
Leuk Res; 2010 Jun; 34(6):700-1. PubMed ID: 20074800
[No Abstract] [Full Text] [Related]
19. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Khong T; Spencer A
Mol Cancer Ther; 2011 Oct; 10(10):1909-17. PubMed ID: 21859842
[TBL] [Abstract][Full Text] [Related]
20. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
Pandey MK; Sung B; Aggarwal BB
Int J Cancer; 2010 Jul; 127(2):282-92. PubMed ID: 19937797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]